- Home
- SCLX vs FTHM Comparison
SCLX vs FTHM Comparison
Compare SCLX & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- FTHM
- Stock Information
- Founded
- SCLX 2011
- FTHM 2010
- Country
- SCLX United States
- FTHM United States
- Employees
- SCLX N/A
- FTHM N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- SCLX Health Care
- FTHM Finance
- Exchange
- SCLX Nasdaq
- FTHM Nasdaq
- Market Cap
- SCLX 35.7M
- FTHM 38.3M
- IPO Year
- SCLX N/A
- FTHM 2020
- Fundamental
- Price
- SCLX $26.28
- FTHM $2.82
- Analyst Decision
- SCLX Strong Buy
- FTHM
- Analyst Count
- SCLX 3
- FTHM 0
- Target Price
- SCLX $367.50
- FTHM N/A
- AVG Volume (30 Days)
- SCLX 230.4K
- FTHM 1.5M
- Earning Date
- SCLX 08-13-2025
- FTHM 11-06-2025
- Dividend Yield
- SCLX N/A
- FTHM N/A
- EPS Growth
- SCLX N/A
- FTHM N/A
- EPS
- SCLX N/A
- FTHM N/A
- Revenue
- SCLX $44,236,000.00
- FTHM $390,032,000.00
- Revenue This Year
- SCLX $89.26
- FTHM $25.22
- Revenue Next Year
- SCLX $203.95
- FTHM $16.19
- P/E Ratio
- SCLX N/A
- FTHM N/A
- Revenue Growth
- SCLX N/A
- FTHM 19.16
- 52 Week Low
- SCLX $3.60
- FTHM $0.65
- 52 Week High
- SCLX $41.30
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- SCLX 76.74
- FTHM 70.20
- Support Level
- SCLX $23.90
- FTHM $1.80
- Resistance Level
- SCLX $19.73
- FTHM $2.98
- Average True Range (ATR)
- SCLX 1.85
- FTHM 0.45
- MACD
- SCLX 0.50
- FTHM 0.09
- Stochastic Oscillator
- SCLX 91.79
- FTHM 83.44
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.